 |
| |
|
|
President's Message |
Dr Peter Riegman
|
Thank you for your interest in ESBB activities. ESBB is the European, Middle Eastern and African Society for Biopreservation and Biobanking a regional chapter of ISBER. I hope you will find ESBB has a lot to offer in the science, support and management of biospecimens and biobanking where those that work with biorepositories can become engaged in many of the organizations activities. ESBB is an organization for those that have an interest in biopreservation and biobanking and is mainly operating through the activity of its members. Therefore, your activities and influence as a member are important for the direction and form of ESBB.
Therefore we welcome not only managers of biobanks / biorepositories to participate, but also vendors marketing products for biorepositories as well as those depending on the supply of biospecimens like scientists and technicians from a variety of disciplines: governmental institutions, pharmacological companies, hospitals, museums including the brokers in between. In addition, those that are concerned with the Ethical, Legal and Social issues involved in collecting and using biospecimens for research.
The playing field of biorepositories is one that is always moving in all of its fields of expertise. The last decade society has seen that biorepositories are very important for innovation in many fields. Especially for environmental, Health and Medical issues advances are expected to result from research done on biospecimens collected in biorepositories. However before such results can be obtained we need to make sure the biospecimens are collected in such a way they are not only stored "Fit for Purpose", where quality issues on biospecimen and on documentation as well as standardization come into play. Since the biospecimens collected today are going to be used perhaps even decades later, we need to be concerned what the demands on quality issues might be in the future. Certainly when large amounts are needed for highly significant experiments have high impact on innovation where many institutes need to cooperate in large consortia.
ESBB has organized its first inaugural meeting in Marseille this year in November. Thanks to all the participants it has become a wonderful success. There were 378 participants representing 33 nationalities and 3 different continents. Currently we are active developing plans for the second meeting to be held in the beautiful city Granada, Spain. A perfect plan that originated from Christian Oste. The second ESBB meeting is going to be even more ambitious than the first. The meeting will be held right after the big Spanish event the meeting of the Spanish Network of Biobanks or "Red de Biobancos".
Next to the meeting we have the working group activities of which many share their activities with ISBER. Within ESBB there are committees in which you can be active. In addition, there activities for our members to found online like LinkedIn or e-mail. Biopreservation and Biobanking as our means of publishing peer reviewed articles for others in the field to read.
I want to thank you for the opportunity you gave me to be your second ESBB president. The important tasks I see before me as president is to give more shape to the still fresh society. To make clear to the members what they need to do if they want to become interactive with ESBB. How to join a WG or committee and make clear what the rules are to change the committee members over the years, so you can be interactive with this fresh society. Shape the fresh chapter relation with ISBER with shared committees and working groups.
Sincerely,
Peter Riegman
ESBB president 2011 - 2012
|
|
|
|
Background Information |
The International Society for Biological and Environmental Repositories (ISBER) is an international society for people interested in the biobanking of human and non-human biological materials. ISBER was formed 11 years ago by members of the US National Institutes of Heath and Centers for Disease Control and it is based in Bethesda, Maryland. It is a very active society with many committees and working groups. Each year ISBER holds an annual general meeting which includes a variety of carefully planned activities to encourage communication and networking: there are lectures, workshops, exhibitor booths, posters, roundtable lunches, social events, committee meetings and a business meeting. In many ways, these provide an excellent model to follow.
One challenge that has inevitably been faced by ISBER, as a US-based international society, has been to provide meetings on other continents that are sufficiently frequent to meet regional needs. To address this need, a European Chapter interest group was formed at ISBER's 2010 annual meeting in Rotterdam (May 2010) and subsequently a discussion group was established on LinkedIn (June 2010), which rapidly grew to over 600 members. In view of the high level of interest, a meeting of 35 members was held in Milan at the end of August 2010, in order to make definitive plans. At this meeting it was decided to establish ESBB as a society serving not only Europe, but also the Middle East and Africa for a variety of reasons including collaborative potential. The initial leadership of the society was decided and officers and committee members were appointed. Based on discussions at the Milan meeting it was decided that ESBB should aim to become a chapter of ISBER, in order to encourage trans-atlantic collaboration and build on the obvious strengths of this sucessful organisation.
|
| |
| Relationship With ISBER |
ESBB became a regional chapter of ISBER in mid 2011. What this means is that the activities of ESBB and ISBER are closely coordinated which leads to mutual benefit. The coordination is achieved by having cross-representation on corresponding committees. So for example, the President of ISBER is an ex-officio member of the ESBB Executive Committee. Similarly, the President of ESBB is an ex-officio member of the ISBER Council. In addition, there are a number of joint activities and so for example members of ESBB are able to join ISBER working groups.
ESBB has a regional focus and all of its annual conferences are in the region of Europe, the Middle East and Africa. In contrast, ISBER has global representation and interests, and its annual conferences are held in the USA, Europe, Asia and Australasia.
It should be noted that ESBB and ISBER are financially independent. Membership of one organisation does not provide membership of the other. However, starting the 1st January 2013, ISBER and ESBB hope to be able to offer reciprocal discounts to members. To facilitate this, ESBB is currently synchronising its financial year with ISBER.
|
| |
Mission & Goals |
The mission of ESBB is to advance the field of biobanking in support of research relating to healthcare, education and the environment.
The goals of ESBB are as follows:
Goal 1. Identify problems in the biobanking field and provide solutions.
Goal 2. Encourage high professional standards in biobanking.
Goal 3. Provide high value membership services for key actors in the biobanking field.
Goal 4. Encourage participation from a wide range of repositories across the EMEA region.
Goal 5. Provide a strong united voice for biobankers in the region, to influence development of their field.
Goal 6. Partner with other organizations involved with, or related to biobanking.
Goal 7. Encourage and support public-private biobank-related partnerships because of their scientific, medical and commercial importance.
Goal 8. Promote stakeholder support for biobanking.
Strategies to achieve these goals have been defined in the ESBB Business Plan. |
|
| |
Operating Procedures |
Operating procedures for ESBB have been drafted along similar lines to those of ISBER. Their primary function is to define the rights of members, the responsibilities of officers and committees and the procedures to be followed to ensure democratic society elections. |
|
|
|
Executive Committee |
The ESBB Executive Committee is chaired by the President, Peter Riegman and includes the following members:
Voting Members
- President: Peter Riegman (NL)
- Past-President: Pasquale De Blasio (IT)
- President-Elect: Rita Lawlor (IT)
- Treasurer: Tobias Schulte in den Bäumen (NL)
- Councilor: Marta Acilu (ES)
- Councilor: Christian Chabannon (FR)
- Councilor: Ann Cooreman (GB)
- Councilor: Hans-Peter Deigner (DE)
-
Councilor: Peter Doran (IE)
- Councilor: Elena Salvaterra (IT)
Non-Voting Members
- Marc Reymond (DE)
- Philippe Van der Hofstadt (BE)
- Stéphane Petit (BE)
- Vincenzo Costigliola (BE)
- Olga Golubnitscha (DE)
- Robert Hewitt (FR) - Executive Officer
- Christian Oste (SP) - Chair, Vendor Committee
- Marianne Henderson (USA) - ISBER President
- Mark Sobel (USA) - ISBER Executive Officer
The Executive Committee as a whole, generally meets by audioconference on a monthly basis to discuss long-term strategy. There is also a Management Subcommittee comprising the President, Vice-President, Treasurer and Executive Officer which meets more frequently to discuss short-term strategy. In addition there are subcommittees for business plan development, financial planning and discussion of membership benefits. |
|
|
| Programme Committee |
The Programme Committee for the 2012 conference in Granada is being chaired by Peter Doran
|
| |
Vendor Committee |
The Vendor Committee is chaired by Christian Oste.
- Marta Acilu - Noray Bioinformatics
- Paolo Concio - Labvantage Solutions Ltd
- Pasquale De Blasio - BioRep s.r.l.
- Michel Depont - Cryo Bio Systems
- Kate Enright - Thermo Fisher Scientific
- Robert Hewitt - Executive Officer
- Jonathan Horan - Vitro
- Laurent Jacotot - Modul-Bio
- Nicole Neubauer - QIAGEN GmbH
- Christian Oste - Bioscope International - Chair
- Egon Pfeifer - ASKION Vertriebs GmbH
- Christian Pioltelli - SOL Group SpA
- Michele Piovella - BioRep Srl
- Antonella Rinaldi - Pyxis Open Solutions s.r.l
- Benjamin Spindler - Sysmex Digitana AG
- Erik Steinfelder - Thermo Fisher Scientific
- Philippe Van der Hofstadt - B & C Group
- Graham Wilson - LabVantage Solutions Ltd
|
| |
Partner Organisations |
|
|
| |
|
| |
|
|
|
Professor Christian Chabannon
Christian Chabannon is a Professor of Medicine at the Université d’Aix-Marseille, and a full member at the Institut Paoli-Calmettes, the Comprehensive Cancer Center in Marseille. Since 2000, he is the head of the Cell Therapy Facility as well as the tumor bank / Biological Resource Center for Oncology at IPC. Previously, Pr. Chabannon trained at the Lyon and Grenoble University Hospitals in France, and at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. He is a board-certified specialist in Hematology and Medical Oncology. His medical and scientific interests lie in hematopoietic stem cell biology and transplantation, the development of cell therapies, and more generally clinical and translational research in hematology and medical oncology. Pr. Chabannon is a member of several scientific societies. He currently serves as President for JACIE, the Joint Accreditation Committee for ISCT Europe and EBMT, which delivers accreditation to European hematopoietic stem cell programs complying with FACT-JACIE standards. He is also the scientific coordinator for Cancéropôle PACA, the regional cancer research network that promotes networking and communication in all aspects of oncology research in the Provence-Alpes-Côte d’Azur area; one of the prominent successes of Cancéropôle PACA has been the establishment of a common and shared web-based catalogue for its three tumor banks.
Contact details: chabannonc(at)marseille.fnclcc.fr. Websites: http://www.institutpaolicalmettes.fr; http://www.univmed.fr; http://www.canceropole-paca.com; http://www.biobank-paca.com
|
|
|
|
Dr. Ann Cooreman
Dr. Ann Cooreman is the co-founder (with Dr. Morag McFarlane) of Tissue Solutions Ltd (www.tissue-solutions.com) based in Glasgow, Scotland. The company helps researchers find human biomaterials for pre-clinical research: fresh, frozen and FFPE tissues, blood products and cell lines, normal and diseased material, all ethically obtained. She is also the company COO. Ann Cooreman started her career as an academic in a very different field but fate led her to become the tissue acquistionist for Scottish Biomedical where she fine-tuned her knowledge of ethics in the UK and Europe with regards to the use of human samples for research. Her experience as Project Manager at Scottish Biomedical and previously at IBM has helped her in growing Tissue Solutions into a niche company, which is establishing a global name for itself after 3 and a half years in the business. Ann Cooreman received a Master’s Degree from the University of Antwerp in Germanic Philology in 1980, Summa Cum Laude, and a PhD in Linguistics from the University of Oregon in 1985. She has authored several peer reviewed articles in journals and books as a linguist but is happier as a business woman than she was as an academic.
Contact details: ann(at)tissue-solutions.com Web page: www.tissue-solutions.com
|
|
|
|
|
|
Pasquale De Blasio - Past-President, ESBB
Pasquale De Blasio, is presently the CEO of BioRep (www.biorep.it), a global service provider biorepository based in Milan, Italy; President of ESBB and Adjunct Associate Professor at Temple University, Philadelphia-PA (USA) and founder of Integrated Systems Engineering S.r.l. (www.isenet.it) operating in development of automation instruments for molecular and cellular biology (e.g Tissue Microarrayers, Biorepositories automation, etc.). Pasquale has more than 35 years of industrial working experience in management positions. He worked for more than 14 years in Industrial and Power Plant design, and over 15 years in analytical instrumentation developments.. He has also matured specific skills in multinational analytical instrumentation companies, as R&D Manager for the developments of HPLC Systems, UV/VIS Spectrophotometers, Ultra Centrifuges and Medical Anaesthesia Systems; and as Industrial Operations Management in the development and manufacturing of Blood Gas and Coagulation Analytical Instruments.. He has also experience with ISO 9001 Quality System, EEC Medical Directive and CE certification. He has a Bachelor of Science in Electrical Engineering from Villanova University, Villanova, Pennsylvania, USA (1976), and a Master Degree in Business Administration from Bocconi University, Milan, Italy (1986). He is co-author of several peer-reviewed scientific papers and co-participants of several industrial patents. Contact details: p.deblasio(at)isenet.it; pasquale.deblasio(at)isenet.it
|
|
|
|
Hans-Peter Deigner
Dr. Hans-Peter Deigner currently is Lab Director at the Fraunhofer Institute IZI / EXIM at the newly established site at Rostock, Germany. During the past three years he applied metabolomics to identify and develop biomarkers at Biocrates AG, Innsbruck, Austria. Hans-Peter has extensive experience in omics and biomarker research including several senior management positions positions in Biotech companies. He authors about 75 peer reviewed articles and 35 patents / patent applications and is a regular reviewer for numerous scientific journals and funding agencies. While holding senior management positions in biotech industry he has developed novel molecular diagnostics from the idea via the prototype to the final commercial product. From 2004-2006 he took up a chair in Biomedicinal Chemistry, University of East Anglia, Norwich, UK. Hans-Peter Deigner graduated in pharmaceutical chemistry, Heidelberg University, Germany and after a position as research associate at Harvard Medical School returned to Heidelberg to finish his habilitation and to work as group leader and senior lecturer/associate professor. His current research interests comprise the integration of omics data and its combinatorial use in biospecimen & biomarker research, systems biology, molecular diagnostics and individualized therapy.
|
|
|
|
|
Dr Peter Doran
Dr. Peter Doran earned his BSc. from Dublin City University in 1998 and his PhD from University College Dublin in 2001. Dr. Doran is a lecturer at the UCD School of Medicine and Medical Science, and Scientific Director of the UCD Clinical Research Centre (CRC). The UCD CRC with facilities at both the Mater Misericordiae and St. Vincent's University Hospitals drives clinical and translational research which is aimed at improving patient care by acting as a catalyst to bring all members of the biomedical research enterprise together to ensure novel health interventions are developed and diffused into Irish healthcare practice. Dr Doran leads the significant biobanking activity completed at the UCD CRC and has been the driver for the creation of national biobanking guidelines. The main focus of his research is the complications associated with HIV and its treatment. Since the introduction of Highly Active Antiretroviral Therapy (HAART), morbidity and mortality have been significantly reduced. However, a number of serious side effects have been seen in these patients. HIV patients are at increased risk of decreased bone density, and osteoporosis. His laboratory is focused on uncovering the effects of both HIV and antiviral treatment on the biology of bone cells. Specifically we are interested in changes in the function of osteoblasts and Mesesnchymal stem cells. Through these investigations we are gaining further insight into the interaction of HIV with the body.
|
|
|
|
|
|
Rita Lawlor - President-Elect, ESBB
Rita Lawlor is a founder and project manager for the ARC-NET (www.arc-net.it) cancer research centre in Verona, Italy. She is head of its Research Biobank involved in European Community funded researches for novel molecular diagnostic markers (http://www.moldiagpaca.eu/), therapeutic targets (http://epcnet.eu), and epidemiological studies in cancer (pangen-eu). She project manages the Italian effort within the International Cancer Genome Consortium (www.icgc.org) and the Italian collaboration with Australia and Canada for pancreas cancer. Member of the working group to define the standards for Research Biobanks of the Veneto Regional Government of Italy. She has more than 20 years international experience. In Japan for 6 years, she developed the first trading systems for top trading Japanese companies. She matured skills in risk analysis, over 10 years developing disaster recovery solutions for financial institutions in Japan and Europe. She acquired experience in on-line education while project managing creation of: a data mining knowledge management platform; and a helicopter technical on-line training course for the Italian police. Her experience took her from financial banking to biological sample banking. She has worked for seven years in cancer research and bio-banking and in dataset definition for Italian National pancreas group and the International Cancer Genome Consortium. Degree in Computer Science (1986) and Master Degree (1992), Trinity College Dublin, Ireland. Diploma and Certified in Project Management with Project Management Institute (PMI). Certificate in Principles of biobanking from the University of Luxemburg. Member of PMI, Italian Societies of Pathology (SIAPEC) and Pancreatology (AISP). Committee member of ESBB. Contact details: rita.lawlor(at)arc-net.it
|
|
|
|
Prof. Marc A. Reymond, MD MBA (AACSB)
Dr Reymond is a board-certified gastrointestinal surgeon. He was trained at the University of Geneva, Switzerland and at Harvard Medical School, Boston, MA. Since 2005, he is Chairman of the Department of Surgery at the Protestant Hospital Bielefeld (www.evkb.de ), an academic hospital with 1500 beds in Germany. He was group leader at the Foundation for Medical Research at the University of Geneva. He has published over 100 peer-reviewed papers in the fields of surgical oncology, of sample preparation, of cancer proteomics, of tumor cell dissemination and research bioethics. He is a reviewer for 20+ journals and grant agencies. He is also serving in the board of two non-profit biobanks (www.stiftung-path.de; www.etsi-med.de ). Dr Reymond is Professor of Surgery at the University of Magdeburg, at the Westphalia University Münster and Honorary Professor at the State Medical Academy, Kyrgyzstan. He is the author of several books. He is heading an annual training course for surgeons on behalf of the German College of Surgeons. Dr Reymond completed a MBA (AACSB) in Science & Technology with LaSalle University, PA. He is the founder of a biotechnology company and holder of two innovation prizes. He is inventor of several patents. Contact details: marc.reymond(at)evkb.de
|
|
|
|
Dr Peter Riegman - ESBB President
Peter Riegman is at present the head of the Erasmus Medical Center Tissue Bank. The tissue bank offers fresh frozen tissue and pathology archival FFPE materials for medical research. The frozen samples are covered with a QA and QC program collected under the rules defined by the Dutch code of conduct. From this position he is involved in four European projects, EurocanPlatform, SPIDIA, EuroBoNeT and BBMRI. He has coordinated the TuBaFrost project, which is still active within the OECI, where he is co-opted board member and chair of the OECI working group biobanking. From 2008 he became ISBER president-elect, 2009-2010 he has been ISBER president, which is followed by the role of past president until 2011. He was elected vice president at the end of 2010 as vice president in ESBB ISBER chapter. In 2011 he became a member of the Editorial board of Biopreservation and Biobanking and of the International Steering Committee of P3G.
|
|
|
|
Dr Elena Salvaterra
Elena Salvaterra is presently working at the Scientific Institute “E. Medea” as senior researcher in the field of Bioethics and Biolaw, where she is coordinating a project on Pediatric Biobanking ELSI. After the degree in Law (1999), she holds a doctorate in “Philosophy of Law” at the University of Milan, Italy, (2004) and a Master Degree in Biolaw (2004). She worked in several universities and research institutes in Italy, including the Biological Resource Center of the Polyclinic Univesity Hospital “Cà Granda” of Milan where she was co-founder and director of the “Laboratory of Bio-Law” from February 2005 to November 2009. Her research interests cover clinical bioethics, biobank-ethics and law, regulatory affairs, robo-ethics, neuroethics and neurolaw. She is author of several peer reviewed publications addressing ethical, legal and social issues related to biobanking. She is a free lance journalist in the field of Science and Technology.
|
|
|
|
Tobias Schulte-in-den-Baumen - Treasurer
|
|
|
|
Philippe Van der Hofstadt
Philippe Van der Hofstadt is CEO of B & C Group, a European niche packaging & logistics company dedicated to clinical research and active on a global scale (www.bnc-group.com).
After the degree of Pharmacist at Université Catholique de Louvain (UCL), Philippe worked at SGS Laboratoires Simon and Biopharma to become Industrial Pharmacist and did a third cycle in Pharmaceutical Engineering. He has worked as Junior Consultant in Regulatory Affairs and Clinical Research with Cogepharm & Pharmarisk in France and Belgium, Sales Manager with SmithKline Beecham Clinical Laboratories' Central Laboratory (now QUEST) in Europe, and was General Manager of CRL-Medinet (Central Laboratory) in the Netherlands.
In 1999, he started the expansion of B & C Group as a niche service provider in clinical research offering innovative & flexible Drug & kit packaging & warehousing, transport, biobanking and drug archiving solutions to Pharma & Biotech companies, CROs, Central Labs and Academic or Research Institutions. Philippe is active in several Professional Associations and is currently:
- President of BeCRO, the Belgian Association of CROs (www.becro.be) , member of EUCROF, the European CRO Federation (www.eucrof.eu),
- President of the VAPI-UPIP (Belgian Association of Industrial Pharmacists),
- Member of the BioWin Biobanking Working Group composed of representatives from commercial Biorepositories, the Belgian Cancer Registry, Universities, Research Laboratories, (Bio)Pharmaceutical and Diagnostic companies.
|
|
|
Ex-Officio Members
|
|
Robert Hewitt - Executive Officer
|
|
|
|
Christian Oste - Chair, Vendor Committee
|
|
|
| |
